(Q26738390)

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

TTF-1 expression in pulmonary adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

ALK testing in non-small cell lung carcinoma: what now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Clinical Implications of Variant ALK FISH Rearrangement Patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

A rare case of an EML4-ALK-rearranged lung adenocarcinoma missed by in situ-hybridization but detected by RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and Amplifications in Non-Small Cell Lung Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

7 January 2021

Quantitative analysis of tumor in bronchial biopsy specimens

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

7 January 2021

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

7 January 2021

Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

7 January 2021

Incorporation of crizotinib into the NCCN guidelines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW302

7 January 2021